- Home
- Equipment
- usa rhode island
- clinical development
Refine by
Applications
- Clinical Immunology and Intensive Care Medicine for Haemophilia
- Clinical Immunology and Intensive Care Medicine for Immunoglobulins
- Clinical Immunology and Intensive Care Medicine for Antibody Deficiency
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiome Therapeutics for Clinical Trials
- Microbiome Therapeutics for Patients and Physicians
- Medical solutions for MiniTC and mini-stem system sector
- Solution for Ultrafast Laser Spectroscopy / Imaging
- Solution for High-Speed 4D Imaging
Clinical Development Equipment & Supplies In Usa Rhode Island
174 equipment items found
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
FB2001 (generic name: Bofutrelvir) is a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19. It is a peptidomimetic compound targeting 3CL-protease based on three-dimensional crystal structure of the protease. Preclinical data has shown it has potent activities in vitro and in ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, placebo-controlled, single and repeated dose, escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VVZ-149 injection in healthy adult ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
Single-dose, escalation clinical trial to evaluate the safety and pharmacokinetics of VVZ-149 injection in healthy elderly ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic gastrectomy in early gastric cancer ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A Randomized, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic and robotic-laparoscopic ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after artificial hip replacement ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
Analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal surgery: a randomized, double-blind, parallel group, placebo-controlled, dose finding ...
Manufactured by:Ariana Pharma based inParis, FRANCE
Ariana® has consolidated multiple, publicly available administrative healthcare admissions databases into a locally searchable observational health data resource of patient hospitalization, outpatient and other episodes, comprising in excess of 6B records. ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
Manufactured by:Apyx Medical Corporation based inClearwater, FLORIDA (USA)
Renuvion cosmetic technology is the result of extensive scientific research and clinical development. Because of its proprietary balance of helium and RF energy, Renuvion has been described as ideal for medical procedures where precision and control are key to an effective ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and Amgen are developing CX-904, a T-cell engaging bispecific Probody candidate against Epidermal Growth Factor Receptor (EGFR) and CD3. The drug candidate is advancing towards IND-enabling studies. CytomX is responsible for the IND filing, targeted for late 2021, and for early clinical development with Amgen leading later stage ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in clinical development for treating osteoporosis. Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.https://www.creative-peptides.com/product/abaloparatide-item-10-101-172-33658.html ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
We have also developed another class of compounds that are novel histone deacetylase inhibitors (HDACi). Designated as our LB-200 series of compounds, these have potential use in the prevention and treatment of neurodegenerative diseases. The series has the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as ...
Manufactured by:Aurinia Pharmaceuticals Inc. based inVictoria, BRITISH COLUMBIA (CANADA)
BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA in ...
Manufactured by:Aurinia Pharmaceuticals Inc. based inVictoria, BRITISH COLUMBIA (CANADA)
Dysregulation of M2 macrophages drives fibrosis. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines, and therefore may have significant clinical applications for autoimmune and fibrotic diseases. It is anticipated that clinical development for AUR300 will commence during the first half of ...
Manufactured by:Genenta Science based inMilano, ITALY
We believe that LVVs are the first choice for ex-vivo gene therapy in humans because they can efficiently transduce HSPCs with potentially large transgenes that will allow us to expand therapeutic options to a multitude of payloads. Most importantly, there is an abundance of safety data generated using these vectors to develop novel medicines currently in ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab so they will attack cancer cells. If clinical ...